0000905718-21-001263.txt : 20211001
0000905718-21-001263.hdr.sgml : 20211001
20211001163052
ACCESSION NUMBER: 0000905718-21-001263
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210924
FILED AS OF DATE: 20211001
DATE AS OF CHANGE: 20211001
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Abingworth LLP
CENTRAL INDEX KEY: 0001397144
STATE OF INCORPORATION: X0
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39138
FILM NUMBER: 211299332
BUSINESS ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
BUSINESS PHONE: 44 (0)20 7534 1500
MAIL ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jasper Therapeutics, Inc.
CENTRAL INDEX KEY: 0001788028
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 842984849
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2200 BRIDGE PKWY SUITE #102
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 6505491400
MAIL ADDRESS:
STREET 1: 2200 BRIDGE PKWY SUITE #102
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: Amplitude Healthcare Acquisition Corp
DATE OF NAME CHANGE: 20190912
3
1
jasper_fm3sep242021.xml
X0206
3
2021-09-24
0
0001788028
Jasper Therapeutics, Inc.
JSPR
0001397144
Abingworth LLP
PRINCES HOUSE 38 JERMYN STREET
LONDON
X0
SW1Y 6DN
UNITED KINGDOM
0
0
1
0
Common Stock
5628558
I
By Abingworth Bioventures VII, LP
On September 24, 2021, pursuant to that certain Business Combination Agreement, dated as of May 5, 2021, by and among the Issuer (f/k/a Amplitude Healthcare Acquisition Corporation), Ample Merger Sub, Inc. ("Merger Sub"), and Jasper Therapeutics, Inc. ("Old Jasper"), Merger Sub merged with and into Old Jasper with Old Jasper surviving as a wholly owned subsidiary of the Issuer (the "Business Combination"). Prior to the consummation of the Business Combination (the "Effective Time"), each share of Series A-1 preferred stock of Old Jasper was converted into Class A common stock of Old Jasper. At the Effective Time, each issued and outstanding share of Class A common stock of Old Jasper was automatically cancelled and extinguished and converted into shares of common stock of the Issuer (the "Shares"). Represents 4,878,558 Shares acquired in the Business Combination and 750,000 Shares acquired in the private placement which closed concurrently with the Business Combination.
The securities of the Issuer are held by Abingworth Bioventures VII, LP ("Abingworth"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth. ALLP holds the reported securities indirectly through Abingworth. ALLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
/s/ John Heard
2021-10-01